BUX — BioMark Diagnostics Income Statement
0.000.00%
Last trade - 00:00
- CA$27.27m
- CA$28.04m
- CA$0.15m
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0.263 | 0 | 0.044 | 0.153 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 0.546 | 1.49 | 1.08 | 1.45 | 1.89 |
Operating Profit | -0.546 | -1.22 | -1.08 | -1.4 | -1.73 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -0.546 | -1.22 | -1.09 | -1.45 | -1.84 |
Net Income After Taxes | -0.546 | -1.22 | -1.09 | -1.45 | -1.84 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.546 | -1.22 | -1.09 | -1.45 | -1.84 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.546 | -1.22 | -1.09 | -1.45 | -1.84 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.008 | -0.017 | -0.015 | -0.021 | -0.025 |